XTLB Stock Chart & Stats
2.10
-0.10(-4.76%)
At close: 4:00 PM EDT
2.10
-0.10(-4.76%)
Day’s Range― - ―
52-Week Range1.60 - 11.80
Previous CloseN/A
Volume0.00
Average Volume (3M)3.17M
Market Cap
₪19.87M
Enterprise Value5.24M
Total Cash (Recent Filing)₪1.14M
Total Debt (Recent Filing)₪138.00K
Price to Earnings (P/E)―
Beta0.55
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding946,243,350
10 Day Avg. Volume3,402,460
30 Day Avg. Volume3,173,045
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-26.57
Price to Sales (P/S)0.00
P/FCF Ratio-6.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
XTLB FAQ
What was XTL Biopharmaceuticals Ltd.’s price range in the past 12 months?
XTL Biopharmaceuticals Ltd. lowest stock price was 1.60 and its highest was 11.80 in the past 12 months.
What is XTL Biopharmaceuticals Ltd.’s market cap?
XTL Biopharmaceuticals Ltd.’s market cap is ₪19.87M.
When is XTL Biopharmaceuticals Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were XTL Biopharmaceuticals Ltd.’s earnings last quarter?
XTL Biopharmaceuticals Ltd. released its earnings results on May 31, 2023. The company reported -0.6 earnings per share for the quarter, missing the consensus estimate of N/A by -0.6.
Is XTL Biopharmaceuticals Ltd. overvalued?
According to Wall Street analysts XTL Biopharmaceuticals Ltd.’s price is currently Overvalued.
Does XTL Biopharmaceuticals Ltd. pay dividends?
XTL Biopharmaceuticals Ltd. does not currently pay dividends.
What is XTL Biopharmaceuticals Ltd.’s EPS estimate?
XTL Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XTL Biopharmaceuticals Ltd. have?
XTL Biopharmaceuticals Ltd. has 946,243,350 shares outstanding.
What happened to XTL Biopharmaceuticals Ltd.’s price movement after its last earnings report?
XTL Biopharmaceuticals Ltd. reported an EPS of -0.6 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.878%.
Which hedge fund is a major shareholder of XTL Biopharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IL:XTLB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to sourcing and advancing medicinal products aimed at treating autoimmune conditions. Its principal experimental compound, hCDR1, is primed for Phase II clinical studies, addressing systemic lupus erythematosus and Sjogren's syndrome. The company operates under a licensing agreement with Yeda Research and Development Company Limited, granting it rights for the research, development, and commercialization of hCDR1 across numerous therapeutic applications. Originally incorporated in 1993 as Xenograft Technologies Ltd., the entity rebranded as XTL Biopharmaceuticals Ltd. in July 1995 and is currently headquartered in Ramat Gan, Israel.